Cargando…

Bioresorbable vascular stents and drug-eluting stents in treatment of coronary heart disease: a meta-analysis

OBJECTIVE: To compare the efficacy and safety of bioresorbable vascular stents (BVS) and drug-eluting stents (DES) in coronary heart disease. METHODS: The full text of clinical studies involving BVS and DES was retrieved in PubMed, Springer, EMBASE, Wiley-Blackwell, and Chinese Journal Full-text Dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Le, Chen, Hao, Luo, Zhurong, Yu, Yunqiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6986072/ https://www.ncbi.nlm.nih.gov/pubmed/31992360 http://dx.doi.org/10.1186/s13019-020-1041-5

Ejemplares similares

Mechanical properties of the everolimus-eluting bioresorbable vascular scaffold compared to the metallic everolimus-eluting stent
por: Dalos, Daniel, et al.
Publicado: (2016)

Coronary Endothelium‐Dependent Vasomotor Function After Drug‐Eluting Stent and Bioresorbable Scaffold Implantation
por: Gomez‐Lara, Josep, et al.
Publicado: (2021)

Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice
por: Lee, Joo Myung, et al.
Publicado: (2023)

Successful treatment of recurrent carotid in-stent restenosis and drug-eluting balloon failure with a coronary bioresorbable vascular scaffold: A case report
por: Giordano, Arturo, et al.
Publicado: (2016)

Three-year outcomes of bioresorbable vascular scaffolds versus second-generation drug-eluting stents: Meta-analysis of randomized trials
por: Ke, Junsong, et al.
Publicado: (2020)

Bioresorbable vascular scaffolds versus conventional drug-eluting stents across time: a meta-analysis of randomised controlled trials
por: Jackson-Smith, Elliot, et al.
Publicado: (2022)

The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective
por: Kawashima, H., et al.
Publicado: (2020)

Conformability in everolimus-eluting bioresorbable scaffolds compared with metal platform coronary stents in long lesions
por: Fam, Jiang Ming, et al.
Publicado: (2017)

Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions
por: Kassaian, SE, et al.
Publicado: (2010)

Drug-Eluting Stent as an Option for Intractable In-Stent Coronary Restenosis
por: Hachinohe, Daisuke, et al.
Publicado: (2011)

Five‐year angiographic, OCT and clinical outcomes of a randomized comparison of everolimus and biolimus‐eluting coronary stents with everolimus‐eluting bioresorbable vascular scaffolds
por: Schukraft, Sara, et al.
Publicado: (2021)

Drug eluting stents: Focus on Cypher™ sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions
por: Chieffo, Alaide, et al.
Publicado: (2007)

Comparison of drug-eluting balloon with repeat drug-eluting stent for recurrent drug-eluting stent in-stent restenosis
por: Wang, Guozhong, et al.
Publicado: (2019)

Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis
por: Bangalore, Sripal, et al.
Publicado: (2013)

Mechanical properties of the drug‐eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug‐eluting stent
por: Barkholt, Trine Ø., et al.
Publicado: (2019)

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial
por: Arroyo, Diego, et al.
Publicado: (2014)

Development of a radiopaque, long-term drug eluting bioresorbable stent for the femoral-iliac artery
por: Ha, Dong-Heon, et al.
Publicado: (2019)

Switching types of drug-eluting stents does not prevent repeated in-stent restenosis in patients with coronary drug-eluting stent restenosis
por: Nojima, Yuhei, et al.
Publicado: (2014)

Mid-term outcomes of bioresorbable vascular scaffolds vs second-generation drug-eluting stents in patients with acute coronary syndromes: A systematic review and meta-analysis
por: Ke, Junsong, et al.
Publicado: (2020)

Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable Polymer
por: Yang, Hyoung-Mo, et al.
Publicado: (2017)

Ureteral stent technology: Drug-eluting stents and stent coatings
por: Yang, Luo, et al.
Publicado: (2015)

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-Years Results from the GABI-R Registry
por: Gori, Tommaso, et al.
Publicado: (2019)

Drug-Eluting Balloons versus Second-Generation Drug-Eluting Stents for Treating In-Stent Restenosis in Coronary Heart Disease after PCI: A Meta-Analysis
por: Xiu, Wen-Juan, et al.
Publicado: (2018)

A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system: the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial
por: Saito, Shigeru, et al.
Publicado: (2014)

Comparison of a Bioresorbable, Magnesium-Based Sirolimus-Eluting Stent with a Permanent, Everolimus-Eluting Metallic Stent for Treating Patients with Acute Coronary Syndrome: the PRAGUE-22 Study
por: Toušek, Petr, et al.
Publicado: (2021)

In-stent restenosis due to delayed healing of abluminal bioresorbable polymer everolimus-eluting stent: insight from histopathological evaluation with directional coronary atherectomy
por: Yamamoto, Hiroyuki, et al.
Publicado: (2021)

Pathogenesis of late in-stent thrombosis after treatment with drug-eluting stents
por: Hao, Hiroyuki
Publicado: (2012)

A randomized multicenter comparison of hybrid sirolimus-eluting stents with bioresorbable polymer versus everolimus-eluting stents with durable polymer in total coronary occlusion: rationale and design of the Primary Stenting of Occluded Native Coronary Arteries IV study
por: Teeuwen, Koen, et al.
Publicado: (2012)

Everolimus-eluting coronary stents
por: Saez, Alejandro, et al.
Publicado: (2010)

Restenosis of a drug eluting stent on the previous bioresorbable vascular scaffold successfully treated with a drug-coated balloon: A case report
por: Jang, Hyun Gyung, et al.
Publicado: (2021)

Coronary Stent Thrombosis: Current Insights into New Drug-Eluting Stent Designs
por: Kim, Hyun Kuk, et al.
Publicado: (2012)

The stenting strategy of drug-eluting stents for coronary artery disease in patients on dialysis
por: Fujita, Hiroshi, et al.
Publicado: (2014)

Mid-Term Follow-Up of Drug-Eluting Stenting for In-Stent Restenosis: Bare-Metal Stents versus Drug-Eluting Stents
por: Faramarzi, Negar, et al.
Publicado: (2013)

Polymer-free drug-eluting stents versus permanent polymer drug-eluting stents: An updated meta-analysis
por: Chen, Yun-lin, et al.
Publicado: (2019)

Drug-eluting stents vs. coronary artery bypass-grafting in coronary heart disease
por: Gorenoi, Vitali, et al.
Publicado: (2008)

Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V(®))
por: Sheiban, Imad, et al.
Publicado: (2008)

A meta-analysis of everolimus-eluting stents versus sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients
por: Ouyang, Hang, et al.
Publicado: (2021)

Long-term outcomes after treatment of in-stent restenosis using the Absorb everolimus-eluting bioresorbable scaffold
por: Madanchi, Mehdi, et al.
Publicado: (2021)

Drug- and Gene-eluting Stents for Preventing Coronary Restenosis
por: Lekshmi, Kamali Manickavasagam, et al.
Publicado: (2017)

Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease
por: Xi, Hongfei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_14qtsumncgp5g4e05b2aegbukl